Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib

This review looks at the pharmacokinetics, safety, and effectiveness of taletrectinib, a novel inhibitor that targets both ROS1 and NTRK, in patients with solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). Objective response rates (ORR), progression-free survival (PFS), intracranial efficacy, and safety profiles are evaluated in the Review using phase I and phase II clinical trials, including both domestic and foreign research projects. Findings show that taletrectinib has a promising anticancer impact, good CNS penetration, and a solid safety record, especially in patients with brain metastases. These results imply that ROS1-positive cancers may benefit from taletrectinib as a treatment.